The authors expect a dramatic increase in demand for molecular radiotherapy services in the U.K. as early as next year, especially if lutetium-177 (Lu-177) PSMA is licensed and approved by the National Institute for Health and Care Excellence for treatment of metastatic prostate cancer.
According to the report, most U.K. regions and nations are not prepared for this coming change. The four nations will need to establish protocols to effectively commission new treatments such as Lu-177 PSMA, as well as rapidly invest in the workforce and physical environments to ensure the safe delivery of these new treatments.
You can download the guidelines free-of-charge from the RCR website.
Copyright © 2021 AuntMinnieEurope.com